昊天發展集團(00474.HK)與伊藤忠就Promethera Biosciences產品訂立合作協議
格隆匯 9 月 15日丨昊天發展集團(00474.HK)發佈公告,2020年9月15日,Aceso-Promethera Asia Company Limited、Promethera Biosciences S.A./N.V及伊藤忠商事株式會社訂立更替及經修訂合作協議,內容有關在亞洲授權、銷售及分銷若干專有的知識產權的治療用途,當中涉及治療人類尿素循環失調(UCD)、慢加急性肝衰竭(ACLF)及非酒精性脂肪肝炎(NASH)的擴增肝臟幹細胞療法及肝臟間質幹細胞療法。
根據披露,集團與Promethera Biosciences成立的合營公司Aceso-Promethera Asia擁有研究、開發、利用及商業化Promethera Biosciences在大中華及東南亞知識產權的獨家權利,為免生疑問,當中不包括與製造有關的任何知識產權;Promethera Biosciences為建基於比利時的再生醫學技術公司,負責開發及商業化用於治療人類急性及慢性肝病患者的幹細胞療法;伊藤忠為一家以東京為本部的領先貿易公司,有意投資於亞洲新興的再生醫學市場。
Aceso-Promethera Asia及伊藤忠將為在亞洲指定地區於協定範圍內治療UCD、ACLF、NASH及其他適應症的產品業務機會研討。預期訂約方將參與信息共享,並主動就於指定地區授權、分銷及銷售產品的商機進行磋商。作為合作其中一環,Promethera Biosciences將負責產品生產。訂約方訂立合作協議旨在發展互惠互利的商業關係及利用各方的競爭優勢於亞洲開發及商業化產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.